• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Silent information regulator 1 (SIRT1), a highly conserved NAD+-dependent
deacetylase, is a cellular regulator that has received extensive attention in recent years and …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Background Renal denervation (RDN) has been shown to lower blood pressure (BP), but its
effects on cardiovascular events have only been preliminarily evaluated. Time in therapeutic …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Background Ultrasound and radiofrequency renal denervation (RDN) have been shown to
safely lower blood pressure (BP) in hypertension. Aims The TARGET BP OFF-MED trial …

Background Renal denervation (RDN) reduces blood pressure (BP) in patients with
uncontrolled hypertension in the absence of antihypertensive medications. Objectives This …

Objectives The aim of this study was to evaluate the long-term (3-year) safety and
effectiveness of endovascular baroreflex amplification (EVBA) from both the European and …

Hypertension is the most common and preventable risk factor for cardiovascular disease
(CVD), accounting for 20% of deaths worldwide. However, 2/3 of people with hypertension …

Arterial hypertension affects about one third of the German population with a prevalence
increasing with age up to 60%. Globally, more than a quarter gedoppelt of the population …